New prostate cancer injection enters first human tests in china
NCT ID NCT07339267
Summary
This early-stage study aims to check the safety and measure how a new drug called ASP5541 moves through the body in Chinese men with advanced prostate cancer. The drug is given as a hip muscle injection alongside standard hormone therapy and prednisone. The main goals are to understand the drug's levels in the blood and identify any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital
RECRUITINGBeijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.